Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of gene marker to multiple myeloma

A multiple myeloma, genetic technology, applied in the field of biomedicine, can solve problems that need further research

Inactive Publication Date: 2017-06-20
刘志国 +2
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the existing technology, such as patents 201610602127.X and 201610599598.X, precision medicine has also been explored, but its clinical application needs further research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gene marker to multiple myeloma
  • Application of gene marker to multiple myeloma
  • Application of gene marker to multiple myeloma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Screening for Gene Markers Related to Multiple Myeloma

[0070] 1. Sample collection

[0071] Bone marrow fluid samples were collected from 6 patients with multiple myeloma and 6 normal subjects, including 3 males and 3 females with confirmed multiple myeloma, with a median age of 55 years. The diagnosis of multiple myeloma was based on WHO criteria for diagnosing multiple myeloma. All the above samples were obtained with the informed consent of the patient and the consent of the organizational ethics committee.

[0072] 2. Preparation of RNA samples

[0073] Extract 5-10ml of human bone marrow fluid from the case group and the control group, and put them into anticoagulant tubes. After the bone marrow cells were extracted, 1ml Trizol reagent (Invitrogen Company) was added, mixed thoroughly, and the specimen was stored at -80°C for RNA extraction.

[0074] The RNA in the sample was extracted by the Trizol method, the purity and concentration of the RNA were...

Embodiment 2

[0083] Example 2 QPCR sequencing verification of differential expression of IFFO1 gene

[0084] 1. Large-sample QPCR verification of differential expression of IFFO1 gene. According to the sample collection method in Example 1, 50 cases of multiple myeloma tissues and 50 cases of normal bone marrow tissues were selected.

[0085] 2. The RNA extraction steps are as described in Example 1.

[0086] 3. Reverse transcription

[0087] 1) Reaction system:

[0088] Add 1 μl of RNA template, 1 μl of random primers, add double distilled water to 12 μl, mix well, centrifuge at low speed at 65°C for 5 min, then place on ice to cool.

[0089] Continue to add the following components to the 12 μl reaction solution:

[0090] 5× reaction buffer 4μl, RNase inhibitor (20U / μl) 1μl, 10mM dNTP mixture 2μl, AMV reverse transcriptase (200U / μl) 1μl; mix well and centrifuge;

[0091] 2) Reverse transcription reaction conditions

[0092] 5 minutes at 25°C, 60 minutes at 42°C, and 5 minutes at 70...

Embodiment 3

[0107] Example 3 Overexpression of IFFO1

[0108] 1. Cell culture

[0109] Take out the cryopreserved human multiple myeloma cell line RPMI8226 and resuscitate it in a culture flask, and use RPMI1640 medium containing 10% fetal bovine serum and 1% P / S at 37°C, 5% CO 2 , Cultivated in an incubator with a relative humidity of 90%. Change the medium once every 2-3 days, and use 0.25% EDTA-containing trypsin for routine digestion and passage.

[0110] Digest the cells in the culture flask with trypsin, press 1×10 6 cells / well were seeded in a 24-well culture plate.

[0111] 2. Construction of gene overexpression vector

[0112] Synthesize specific PCR amplification primers, the primer sequences are as follows:

[0113] Forward primer: 5'-CCGAAGCTTGCCACCATGAATCCGTTATTCG-3' (SEQ ID NO.7)

[0114] Reverse primer: 5'-CGGCTCGAGTCTCATGGAGCTGTCAGATGAG-3' (SEQ ID NO.8)

[0115] Two restriction enzyme sites, HindIII and XhoI, were added to the 5' end primer and the 3' end primer, re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a gene marker to multiple myeloma. The gene marker IFFO1 has down-regulated expression in multiple myeloma tissues; the gene marker can be used for early diagnosis of patients with the multiple myeloma through detecting an expression level of the IFFO1. A further experiment proves that expression of the IFFO1 is up-regulated and proliferation of multiple myeloma cells can be effectively inhibited; the IFFO1 can be used for treating the multiple myeloma. The invention also discloses a method for screening potential substances for treating the multiple myeloma, and the expression level of the IFFO1 or the activity of expression products can be up-regulated or increased through the screened potential substances.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of a gene marker in multiple myeloma, in particular to the gene marker being IFFO1. Background technique [0002] Multiple myeloma (multiple myeloma, MM) is a kind of malignant tumor that occurs in incompletely differentiated plasma cells, and is the most common type of malignant plasma cell disease. It is characterized by the proliferation and accumulation of abnormal clonal plasma cells (ie, myeloma cells) in the bone marrow, and clinical manifestations such as repeated infection, osteolytic lesions, anemia, and renal insufficiency. Its annual incidence rate is about 4 / 100,000, accounting for 10% of hematologic malignancies and 0.8% of all malignancies, and belongs to middle-aged and elderly diseases. In my country, the median age of onset of patients is mostly 50-60 years old, but with the gradual aging of the population in my country, the incidence and mortality of MM...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/574A61K45/00A61P35/00
CPCA61K45/00C12Q1/6886C12Q2600/136C12Q2600/158G01N33/57407G01N33/57484G01N2333/47
Inventor 刘志国高利波孙长法
Owner 刘志国